Breast screening attendance of Aboriginal and Torres Strait Islander women in the Northern Territory of Australia.

CONCLUSIONS: Factors associated with fewer visits to screening were similar for both groups of women, except for language which was significant only for Indigenous women, and remoteness which was significant only for non-Indigenous women. Implications for public health: Health communication in Indigenous languages may be key in encouraging participation and retaining Indigenous women in BreastScreen; improving access for remote-living non-Indigenous women should also be addressed. PMID: 31268228 [PubMed - as supplied by publisher]
Source: Australian and New Zealand Journal of Public Health - Category: International Medicine & Public Health Authors: Tags: Aust N Z J Public Health Source Type: research

Related Links:

Healthy women age 75 and older may not benefit from continued breast cancer...Read more on AuntMinnie.comRelated Reading: Is breast screening beneficial for sickly older women? ACP pushes breast cancer screening start from 40 to 50 DBT screening mammography benefits women over 65 Screening mammography still good for older women Age, not density, predicts interval breast cancer result
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (phar...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
China has an increasing burden of breast cancer, but with a population of dense breast patients, the diagnostic efficiency of conventional digital mammography was attenuated. Our study suggested that CESM exhibited an excellent diagnostic efficiency and a moderate correlation in lesion size estimation compared to DCE ‐MRI and pathology, supporting it to be an alternative to DCE‐MRI in breast cancer detection and diagnosis, especially for exclusion diagnosis in dense breast patients. AbstractBackgroundChina has an increasing burden of breast cancer. However, with a large population of dense breast patients, the diagnost...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
AbstractBreast cancer (BC) is the most common malignancy in women with a significant increasing incidence during the reproductive life. However, based on the newest anti-cancer molecular targeting drugs, successful treatments lead to the disease healing particularly in young patients, thus refreshing their motherhood programs. However, as effect of the BC treatment, a premature depletion of the ovarian follicle reserve occurs in more than one-third of patients resulting in permanent infertility. To prevent the cancer treatment-related infertility (CTRI), several options are today utilized. Besides the ovary suppression by ...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Canadian researchers have developed a prototype of a breast cancer screening...Read more on AuntMinnie.comRelated Reading: AI helps characterize breast masses on ultrasound iCAD features AI software for breast imaging at RSNA UCSF launches AI center for medical imaging Deep learning enhances breast cancer risk assessment iCAD partners with Swedish team on AI for breast cancer
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
PURPOSE: Cross-sectional studies suggest that falls are prevalent among older breast cancer survivors. However, fall risk in this population has not been comprehensively examined. Therefore, we compared fall risk in older women post-breast cancer diagnosis...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
MONDAY, Feb. 24, 2020 -- For women aged 75 years or older, continuing annual breast cancer screening does not result in significant reductions in eight-year breast cancer mortality compared with stopping screening, according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Conditions:   Advanced Solid Tumor;   Breast Neoplasms Interventions:   Drug: BPI-1178;   Drug: Fulvestrant;   Drug: Letrozole Sponsor:   Beta Pharma (Suzhou) Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-positive Breast Cancer Intervention:   Diagnostic Test: TCHP Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Advanced Solid Tumor;   Breast Neoplasms Interventions:   Drug: BPI-1178;   Drug: Fulvestrant;   Drug: Letrozole Sponsor:   Beta Pharma (Suzhou) Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Australia Health | Breast Cancer | Cancer | Cancer & Oncology | International Medicine & Public Health | New Zealand Health | Women